Nehra, Geetika
Andrews, Shannon
Rettig, Joan
Gould, Michael N.
Haag, Jill D.
Howard, Steven P.
Thorne, Robert G.
Funding for this research was provided by:
University of Wisconsin-Madison Startup Grant (135 PRJ48TR, 135 PRJ48TR)
Michael J Fox Foundation Training Pipeline Grant (135 PRJ82AZ, 135 PRJ82AZ)
University of Wisconsin Carbone Cancer Center Support Grant P30 (CA014520, CA014520)
Article History
Received: 15 December 2020
Accepted: 22 February 2021
First Online: 18 March 2021
Competing interests
: Dr. Steven Howard is a principal investigator for NEO100-01, a Phase 1/2A study of the monoterpene, perillyl alcohol (NEO100) in patients with recurrent glioblastoma (NCT02704858). Dr. Michael Gould serves as a scientific advisor for NeOnc Technologies, Inc. (NTI), an early-stage cancer biotechnology company that developed NEO100 (a novel, highly purified form of perillyl alcohol). Dr. Robert Thorne is employed full-time as a Denali Fellow at Denali Therapeutics Inc., a for-profit biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases. Dr. Thorne is also appointed as an Adjunct Associate Professor in the Department of Pharmaceutics, University of Minnesota-Twin Cities. The authors declare that this research was conducted in the absence of commercial or financial relationships that could be construed as a potential conflict of interest. Dr. Geetika Nehra, Dr. Shannon Andrews, Dr. Jill Haag, and Ms. Joan Rettig have no competing interests to declare.